

SUPPLEMENTARY TABLES

Supplementary Table 1. Baseline demographic characteristics of people receiving either ChAdOx1, BNT162b2 or mRNA-1273 vaccines or testing positive to SARS-CoV-2 virus (in those vaccinated with either vaccine), in England between 1 December 2020 until 15 November 2021. Figures are column % (counts).

	ChAdOx1	BNT162b2	mRNA-1273	ChAdOx1	BNT162b2	mRNA-1273	ChAdOx1	BNT162b2	mRNA-1273	Positive SARS-CoV-2 test*
	1 dose (n = 42,200,614)			2 dose (n = 38,347,981)			3 dose (n = 10,978,507)			(n = 5,185,772)
	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)
Total number of people	20,646,456	20,391,600	1,162,558	20,059,058	17,294,004	1,039,919	35,608	10,599,183	343,716	5,185,772
Sex										
Women	49.3 (10182140)	49.0 (9985535)	38.4 (446579)	49.4 (9905031)	50.1 (8657542)	39.0 (405748)	57.2 (20369)	56.5 (5987783)	51.6 (177238)	52.2 (2707945)
Men	43.1 (8900093)	40.2 (8199395)	42.0 (488323)	43.2 (8657222)	39.6 (6849358)	41.8 (434478)	37.4 (13331)	40.3 (4274761)	44.2 (151816)	40.4 (2095960)
Not recorded	7.6 (1564224)	10.8 (2206669)	19.6 (227656)	7.5 (1496805)	10.3 (1787103)	19.2 (199693)	5.4 (1908)	3.2 (336639)	4.3 (14662)	7.4 (381867)
Age										
Mean age (SD)	54.9 (14.8)	43.6 (22.3)	32.1 (9.4)	55.0 (14.7)	47.3 (21.6)	32.4 (9.4)	62.5 (17.2)	66.7 (15.4)	63.2 (12.4)	42.0 (18.2)
13-17 years	0.0 (10212)	9.3 (1887751)	0.0 (556)	0.0 (9064)	1.3 (220744)	0.0 (248)	0.1 (22)	0.1 (7422)	0.0 (170)	7.1 (367113)
18-29 years	5.2 (1080573)	24.6 (5009612)	43.2 (502147)	5.1 (1020629)	24.8 (4281647)	41.5 (431451)	4.2 (1495)	2.8 (296943)	2.2 (7516)	22.2 (1151541)
30-39 years	7.9 (1633888)	21.8 (4449421)	36.0 (418848)	7.7 (1553370)	23.3 (4034166)	36.7 (381825)	6.3 (2250)	4.3 (455032)	3.6 (12351)	18.0 (931836)
40-49 years	22.1 (4563009)	8.6 (1752175)	18.6 (216106)	22.0 (4404792)	9.3 (1615419)	19.7 (204584)	11.9 (4229)	6.5 (692898)	6.3 (21712)	19.0 (983809)

50-59 years	27.5 (5673107)	8.2 (1665317)	1.5 (17748)	27.6 (5543761)	9.3 (1608620)	1.4 (14750)	19.2 (6845)	13.4 (1424029)	17.3 (59467)	16.9 (878706)
60-69 years	19.8 (4083537)	8.7 (1766207)	0.4 (5184)	20.0 (4012352)	10.0 (1737947)	0.5 (4847)	18.2 (6498)	21.0 (2223266)	39.6 (136187)	8.9 (462660)
70-79 years	13.4 (2762915)	9.7 (1973783)	0.1 (1542)	13.5 (2717662)	11.3 (1952441)	0.2 (1700)	24.1 (8586)	32.9 (3492004)	26.0 (89442)	4.5 (235613)
80-89 years	3.1 (630417)	7.9 (1619014)	0.0 (369)	3.0 (605236)	9.2 (1587386)	0.0 (438)	11.9 (4239)	16.2 (1718395)	4.1 (14157)	2.5 (127574)
90+ years	1.0 (208754)	1.3 (268204)	0.0 (56)	1.0 (192180)	1.5 (255591)	0.0 (75)	4.1 (1444)	2.7 (289173)	0.8 (2714)	0.9 (46910)
Not recorded	0.0 (301)	5.1 (1030662)	0.0 (47)	0.0 (107)	0.1 (13228)	0.0 (11)	< 0.1 (1)	0.0 (102)		4.0 (208182)
Ethnicity										
White	67.8 (13998166)	63.7 (12989545)	53.3 (619541)	68.0 (13632603)	64.4 (11139124)	53.7 (558043)	73.4 (26148)	76.7 (8131980)	76.2 (261992)	66.8 (3461571)
Other ethnic groups	8.1 (1672963)	9.5 (1936026)	7.6 (88043)	8.0 (1601621)	8.7 (1508302)	7.2 (75218)	7.9 (2808)	5.8 (618083)	4.0 (13747)	10.6 (549690)
Ethnicity not recorded	24.1 (4975328)	26.8 (5466028)	39.1 (454974)	24.1 (4824834)	26.9 (4646577)	39.1 (406658)	18.7 (6652)	17.4 (1849120)	19.8 (67977)	22.6 (1174511)
History of myocarditis										
Prior myocarditis	0.0 (1836)	0.0 (1608)	0.0 (65)	0.0 (1776)	0.0 (1482)	0.0 (56)	0.0 (10)	0.0 (1289)	0.0 (38)	0.0 (623)
COVID-19 status										
No covid	87.9 (18150536)	87.5 (17849752)	87.3 (1014636)	88.0 (17648006)	88.7 (15341130)	87.8 (913362)	88.6 (31559)	92.6 (9812390)	93.0 (319628)	-
Covid prior vaccination	5.9 (1226752)	7.4 (1513590)	8.1 (94199)	5.9 (1181865)	6.3 (1083950)	7.7 (79838)	6.5 (2329)	4.0 (422009)	3.5 (12122)	54.7 (2834579)
Covid after 1st dose	0.7 (136878)	2.6 (525639)	3.1 (36443)	0.5 (97652)	2.1 (365674)	2.8 (29318)	0.8 (296)	0.7 (75604)	0.3 (1088)	13.5 (698993)

Covid after 2nd dose	5.4 (1111972)	2.3 (474831)	1.5 (17274)	5.5 (1111209)	2.7 (475472)	1.7 (17393)	1.1 (390)	2.3 (242891)	2.9 (10092)	30.9 (1604087)
Covid after 3rd dose	0.1 (20319)	0.1 (27787)	< 0.1 (6)	0.1 (20326)	0.2 (27777)	< 0.1 (8)	2.9 (1034)	0.4 (46289)	0.2 (786)	0.9 (48113)
Number of doses										
One dose	2.6 (538297)	15.4 (3145304)	10.7 (124782)	-	-	-	-	-	-	13.4 (695253)
Two doses	73.4 (15145207)	55.1 (11231447)	89.2 (1037051)	75.2 (15091876)	65.3 (11284348)	99.9 (1038375)	-	-	-	70.9 (3675578)
Three doses	24.0 (4962953)	29.5 (6014848)	0.1 (725)	24.8 (4967182)	34.7 (6009655)	0.1 (1544)	100.0 (35608)	100.0 (10599183)	100.0 (343716)	15.7 (814941)
Type of vaccines										
Two doses of ChAdOx1	97.0 (20018696)	-	-	99.8 (20018696)	-	-	82.1 (29244)	44.3 (4692400)	66.7 (229396)	46.4 (2406251)
Two doses of BNT162b2	-	84.4 (17203272)	-	-	99.5 (17203272)	-	5.6 (1994)	55.5 (5882812)	33.0 (113477)	37.4 (1940244)
Two doses of mRNA-1273	-	-	88.9 (1033088)	-	-	99.3 (1033088)	< 0.1 (5)	0.0 (320)	0.1 (259)	2.4 (125757)

*amongst vaccinated

Supplementary Table 2: Demographic and clinical characteristics of patients who were admitted to hospital for myocarditis in the 28 days following a COVID-19 vaccine first, second dose and third dose or SARS-CoV-2 infection amongst the vaccinated population in England from 1 December 2020 until 15 November 2021 (cells with < 5 are suppressed).

	Myocarditis										
	Baseline	Risk set (1-28 days post)									
		ChAdOx1 (1 st dose)	ChAdOx1 (2 nd dose)	ChAdOx1 (3 rd dose)	BNT162b2 (1 st dose)	BNT162b2 (2 nd dose)	BNT162b2 (3 rd dose)	mRNA-1273 (1 st dose)	mRNA-1273 (2 nd dose)	mRNA-1273 (3 rd dose)	Positive SARS- CoV-2 test
Total number of people	1696	139	89	0	120	114	39	11	40	0	177
Sex											
Women	41.7 (697)	41.7 (58)	27.0 (24)	-	42.5 (51)	29.8 (34)	41.0 (16)	*	*	-	40.7 (72)
Men	58.7 (995)	58.3 (81)	73.0 (65)	-	56.7 (68)	70.2 (80)	59.0 (23)	81.8 (9)	90.0 (36)	-	59.3 (105)
Age											
Mean age (SD)	53.8 (19.6)	57.5 (17.6)	54.2 (18.1)	-	49.7 (24.1)	45.9 (25.0)	68.4 (17.4)	27.0 (9.5)	24.9 (6.3)	-	61.5 (17.9)
<40 years	26.2 (444)	14.4 (20)	25.8 (23)	-	44.2 (53)	57.0 (65)	*	90.9 (10)	97.5 (39)	-	14.1 (25)
>=40 years	73.8 (1252)	85.6 (119)	74.2 (66)	-	55.8 (67)	43.0 (49)	92.3 (36)	*	*	-	85.9 (152)
Deaths	9.1 (155)	24.5 (34)	7.9 (7)	-	15.0 (18)	10.5 (12)	20.5 (8)	-	-	-	6.8 (12)
Covid Status											
No covid	-	74.1 (103)	84.3 (75)	-	73.3 (88)	91.2 (104)	84.6 (33)	54.5 (6)	90.0 (36)	-	-
Covid prior vaccination	-	12.9 (18)	11.2 (10)	-	10.0 (12)	*	*	*	*	-	63.8 (113)
Covid after 1st dose	-	10.8 (15)	*	-	14.2 (17)	*	-	*	*	-	15.8 (28)

Covid after 2nd dose	-	*	*	-	*	*	*	-	-	-	20.3 (36)
Covid after 3rd dose	-	-	-	-	*	-	-	-	-	-	-
One dose	-	44.6 (62)	-	-	53.3 (64)	-	-	90.9 (10)	-	-	15.3 (27)
Two doses	-	41.0 (57)	78.7 (70)	-	25.0 (30)	76.3 (87)	-	*	100.0 (40)	-	63.8 (113)
Three doses	-	14.4 (20)	21.3 (19)	-	21.7 (26)	23.7 (27)	100.0 (39)	-	-	-	20.9 (37)
Two doses of ChAdOx1	-	51.8 (72)	98.9 (88)	-	-	-	38.5 (15)	-	-	-	53.1 (94)
Two doses of BNT162b2	-	-	-	-	44.2 (53)	99.1 (113)	61.5 (24)	-	-	-	29.9 (53)
Two doses of mRNA-1273	-	-	-	-	-	-	-	*	100.0 (40)	-	*
Lag between first and second doses >= 28 days	-	54.7 (76)	100.0 (89)	-	45.8 (55)	96.5 (110)	92.3 (36)	*	100.0 (40)	-	84.2 (149)

Supplementary Table 3: Incidence rate ratios (IRR 95% CI) for the main analysis and by age group (aged 40 or younger, older than 40) and sex (female and male) for the outcomes in pre-defined risk periods immediately before and after exposure to vaccination and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from December 1 2020 to November 15 2021 (cells with * are suppressed).

	ChAdOx1	BNT162b2	mRNA-1273	ChAdOx1	BNT162b2	mRNA-1273	ChAdOx1	BNT162b2	mRNA-1273	Positive SARS-CoV-2 test*
	1 dose (n = 42,200,614)			2 dose (n = 38,347,981)			3 dose (n = 10,978,507)			(n = 5,185,772)
	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)	Col % (counts)
Total number of people	20,646,456	20,391,600	1,162,558	20,059,058	17,294,004	1,039,919	35,608	10,599,183	343,716	5,185,772

Sex & Age subgroup										
Male aged < 40 years old	992,510	4,517,315	383,899	943,070	3,282,074	336,105	1,236	199,914	6,165	949,941
Male aged >= 40 years old	7,907,552	3,682,041	104,422	7,714,148	3,567,272	98,372	12,095	4,074,840	135,651	1,146,015
Female aged < 40 years old	1,502,095	5,054,889	348,846	1,427,406	3,847,428	312,891	2,141	502,825	12,763	1,256,488
Female aged >= 40 years old	8,680,029	4,930,590	97,733	8,477,618	4,810,093	92,857	18,228	5,484,946	164,475	1,451,451

Supplementary Table 4: Incidence rate ratios (IRR 95% CI) for the main analysis and by age group (aged 40 or younger, older than 40) and sex (female and male) for the outcomes in pre-defined risk periods immediately before and after exposure to vaccination and before and after a positive SARS-CoV-2 test result, adjusted for calendar time from 1 December 2020 to 15 November 2021 (cells with * are suppressed).

	ChAdOx1nCoV-19 vaccine		BNT162b2 mRNA vaccine		mRNA-1273 vaccine		Positive SARS-CoV-2 test	
Time period	events		IRR (95% CI)		events		IRR (95% CI)	
Main analysis								
Baseline*	1696	1.00	1696	1.00	1696	1.00	2268	1.00
Pre-risk**	283	0.71 (0.62, 0.81)	283	0.71 (0.62, 0.81)	283	0.71 (0.62, 0.81)	43	2.20 (1.58, 3.06)
0 day: 1st dose/positive test	*	0.55 (0.14, 2.20)	*	1.05 (0.34, 3.27)	*	n/a	51	68.70 (50.50, 93.47)
1-7 days: 1st dose/positive test	47	1.77 (1.30, 2.41)	35	1.64 (1.16, 2.32)	8	6.09 (2.82, 13.11)	89	17.28 (13.46, 22.18)
8-14 days: 1st dose/positive test	34	1.21 (0.85, 1.72)	31	1.34 (0.93, 1.94)	*	1.03 (0.23, 4.57)	47	9.20 (6.70, 12.63)
15-21 days: 1 st dose/positive test	29	1.02 (0.70, 1.50)	25	1.08 (0.72, 1.62)	*	n/a	23	4.53 (2.94, 6.97)
22-28 days: 1st dose/positive test	29	1.03 (0.70, 1.50)	29	1.33 (0.91, 1.94)	*	n/a	18	3.36 (2.07, 5.44)
0 day: 2nd dose	*	0.60 (0.15, 2.40)	*	n/a	*	n/a		
1-7 days: 2nd dose	14	0.60 (0.35, 1.02)	48	2.64 (1.96, 3.56)	36	46.73 (28.58, 76.42)		
8-14 days: 2nd dose	29	1.23 (0.84, 1.79)	27	1.51 (1.03, 2.23)	*	n/a		
15-21 days: 2nd dose	19	0.80 (0.51, 1.27)	24	1.35 (0.90, 2.04)	*	2.79 (0.66, 11.70)		
22-28 days: 2nd dose	27	1.13 (0.76, 1.66)	15	0.84 (0.50, 1.41)	*	n/a		

0 day: 3rd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 3rd dose	*	n/a	12	1.64 (0.91, 2.96)	*	n/a		
8-14 days: 3rd dose	*	n/a	14	2.48 (1.42, 4.33)	*	n/a		
15-21 days: 3rd dose	*	n/a	12	3.02 (1.65, 5.52)	*	n/a		
22-28 days: 3rd dose	*	n/a	*	n/a	*	n/a		
Age <40 & Male								
Baseline*	304	1.00	304	1.00	304	1.00	484	1.00
Pre-risk**	34	0.61 (0.42, 0.88)	34	0.61 (0.42, 0.88)	34	0.61 (0.42, 0.88)	9	1.33 (0.65, 2.69)
0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	8	29.82 (14.06, 63.26)
1-7 days: 1st dose/positive test	8	3.26 (1.53, 6.91)	16	2.98 (1.75, 5.07)	6	7.97 (3.17, 20.05)	8	4.63 (2.19, 9.78)
8-14 days: 1st dose/positive test	*	0.80 (0.19, 3.28)	13	2.20 (1.22, 3.94)	*	2.05 (0.46, 9.16)	*	n/a
15-21 days: 1 st dose/positive test	*	1.24 (0.38, 3.99)	*	0.35 (0.09, 1.41)	*	n/a	*	n/a
22-28 days: 1st dose/positive test	*	n/a	8	1.42 (0.69, 2.93)	*	n/a	*	2.25 (0.81, 6.22)
0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 2nd dose	*	1.14 (0.27, 4.73)	33	8.05 (5.37, 12.06)	32	54.65 (29.74, 100.40)		
8-14 days: 2nd dose	10	5.36 (2.67, 10.78)	9	2.24 (1.13, 4.46)	*	n/a		
15-21 days: 2nd dose	*	1.01 (0.24, 4.17)	10	2.46 (1.27, 4.74)	*	3.57 (0.82, 15.60)		
22-28 days: 2nd dose	7	3.21 (1.43, 7.22)	*	0.94 (0.35, 2.57)	*	n/a		
0 day: 3rd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 3rd dose	*	n/a	*	n/a	*	n/a		
8-14 days: 3rd dose	*	n/a	*	n/a	*	n/a		
15-21 days: 3rd dose	*	n/a	*	n/a	*	n/a		
22-28 days: 3rd dose	*	n/a	*	n/a	*	n/a		
Age >= 40 & Male								
Baseline*	691	1.00	691	1.00	691	1.00	897	1.00
Pre-risk**	148	0.81 (0.67, 0.99)	148	0.81 (0.67, 0.99)	148	0.81 (0.67, 0.99)	16	2.64 (1.53, 4.57)

0 day: 1st dose/positive test	*	n/a	*	n/a	*	n/a	23	100.01 (62.18, 160.83)
1-7 days: 1st dose/positive test	20	1.43 (0.89, 2.29)	6	0.84 (0.37, 1.91)	*	n/a	45	27.54 (18.87, 40.21)
8-14 days: 1st dose/positive test	21	1.38 (0.87, 2.21)	*	0.55 (0.20, 1.50)	*	n/a	23	13.44 (8.38, 21.55)
15-21 days: 1 st dose/positive test	13	0.84 (0.47, 1.49)	9	1.16 (0.58, 2.29)	*	n/a	13	7.37 (4.08, 13.31)
22-28 days: 1st dose/positive test	14	0.88 (0.51, 1.52)	10	1.24 (0.65, 2.39)	*	n/a	10	5.38 (2.78, 10.42)
0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 2nd dose	10	0.78 (0.41, 1.49)	5	0.65 (0.27, 1.59)	*	n/a		
8-14 days: 2nd dose	13	1.05 (0.59, 1.84)	5	0.65 (0.27, 1.60)	*	n/a		
15-21 days: 2nd dose	11	0.92 (0.50, 1.69)	7	0.93 (0.44, 2.00)	*	n/a		
22-28 days: 2nd dose	10	0.87 (0.46, 1.64)	7	0.92 (0.43, 1.97)	*	n/a		
0 day: 3rd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 3rd dose	*	n/a	*	0.99 (0.31, 3.15)	*	n/a		
8-14 days: 3rd dose	*	n/a	10	4.41 (2.22, 8.73)	*	n/a		
15-21 days: 3rd dose	*	n/a	6	3.83 (1.61, 9.08)	*	n/a		
22-28 days: 3rd dose	*	n/a	*	n/a	*	n/a		
Age <40 & Female								
Baseline*	140	1.00	140	1.00	140	1.00	176	1.00
Pre-risk**	13	0.43 (0.24, 0.77)	13	0.43 (0.24, 0.77)	13	0.43 (0.24, 0.77)	*	n/a
0 day: 1st dose/positive test	*	n/a	*	6.41 (1.55, 26.51)	*	n/a	*	37.07 (10.55, 130.19)
1-7 days: 1st dose/positive test	5	2.86 (1.07, 7.60)	*	1.36 (0.42, 4.39)	*	n/a	5	10.09 (3.67, 27.70)
8-14 days: 1st dose/positive test	*	n/a	6	2.51 (1.05, 5.98)	*	n/a	*	n/a
15-21 days: 1 st dose/positive test	*	n/a	*	1.85 (0.66, 5.17)	*	n/a	*	8.03 (2.33, 27.69)
22-28 days: 1st dose/positive test	*	n/a	*	n/a	*	n/a	*	3.87 (0.88, 16.98)
0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 2nd dose	*	n/a	5	3.11 (1.23, 7.86)	*	28.49 (6.22, 130.41)		
8-14 days: 2nd dose	*	n/a	*	2.58 (0.92, 7.22)	*	n/a		
15-21 days: 2nd dose	*	n/a	*	n/a	*	n/a		

22-28 days: 2nd dose	*	1.18 (0.28, 5.00)	*	n/a	*	n/a		
0 day: 3rd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 3rd dose	*	n/a	*	n/a	*	n/a		
8-14 days: 3rd dose	*	n/a	*	n/a	*	n/a		
15-21 days: 3rd dose	*	n/a	*	n/a	*	n/a		
22-28 days: 3rd dose	*	n/a	*	n/a	*	n/a		
Age >= 40 & Female								
Baseline*	557	1.00	557	1.00	557	1.00	706	1.00
Pre-risk**	88	0.63 (0.49, 0.81)	88	0.63 (0.49, 0.81)	88	0.63 (0.49, 0.81)	17	3.93 (2.25, 6.86)
0 day: 1st dose/positive test	*	1.50 (0.37, 6.11)	*	n/a	*	n/a	17	96.00 (55.17, 167.06)
1-7 days: 1st dose/positive test	14	1.46 (0.83, 2.56)	10	1.40 (0.72, 2.74)	*	n/a	31	25.39 (16.17, 39.87)
8-14 days: 1st dose/positive test	11	1.09 (0.58, 2.03)	8	1.05 (0.50, 2.20)	*	n/a	22	17.85 (10.79, 29.53)
15-21 days: 1st dose/positive test	12	1.18 (0.64, 2.15)	9	1.24 (0.62, 2.48)	*	n/a	6	4.87 (2.09, 11.36)
22-28 days: 1st dose/positive test	14	1.41 (0.80, 2.47)	11	1.73 (0.92, 3.27)	*	n/a	*	1.63 (0.40, 6.72)
0 day: 2nd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 2nd dose	*	0.21 (0.05, 0.86)	5	0.80 (0.33, 1.97)	*	n/a		
8-14 days: 2nd dose	6	0.63 (0.28, 1.44)	9	1.43 (0.72, 2.82)	*	n/a		
15-21 days: 2nd dose	6	0.63 (0.28, 1.42)	7	1.11 (0.52, 2.39)	*	n/a		
22-28 days: 2nd dose	8	0.83 (0.41, 1.70)	*	0.63 (0.23, 1.70)	*	n/a		
0 day: 3rd dose	*	n/a	*	n/a	*	n/a		
1-7 days: 3rd dose	*	n/a	8	2.32 (1.09, 4.94)	*	n/a		
8-14 days: 3rd dose	*	n/a	*	1.09 (0.34, 3.56)	*	n/a		
15-21 days: 3rd dose	*	n/a	5	2.28 (0.88, 5.93)	*	n/a		
22-28 days: 3rd dose	*	n/a	*	n/a	*	n/a		

*Same for each exposure.

** -28-1 days prior to each vaccine dose or positive test. Same for each exposure.

Supplementary table 5: Measures of effect of vaccinations and SARS-CoV-2 infections presented in absolute terms, number needed to expose for one excess event; excess events per 1 million exposed. Only significant increased risks were reported over the 1-28 days post exposure. When IRR were not significant over the 1-28 days post-vaccine, absolute measures were not given.

	Excess events per 1,000,000 exposed (95% CI)				
	Main analysis	Male aged < 40	Male aged >= 40	Female aged < 40	Female aged >= 40
ChAdOx1					
1st dose	1 (0, 2)	-	-	-	-
2nd dose	-	14 (8, 17)	-	-	-
3rd dose	-	-	-	-	-
BNT162b2					
1st dose	2 (1, 2)	3 (1, 5)	-	-	-
2nd dose	2 (2, 3)	12 (10, 13)	-	-	-
3rd dose	2 (1, 2)	13 (7, 15)	3 (2, 4)	-	-
mRNA-1273					
1st dose	-	12 (1, 17)	-	-	-
2nd dose	36 (34, 37)	101 (95, 104)	-	8 (4, 9)	-
3rd dose	-	-	-	-	-
SARS-CoV-2					
Positive test	30 (29, 31)	7 (2, 11)	73 (71, 75)	7 (6, 8)	39 (37, 40)

Supplementary table 6: ICD-10 codes used to identify cases with each outcome.

Outcome	ICD-10 code and description
Myocarditis	I40 - Acute myocarditis I400 - Infective myocarditis I401 - Isolated myocarditis I408 - Other acute myocarditis I409 - Acute myocarditis, unspecified I41 - Myocarditis in diseases classified elsewhere I410 - Myocarditis in bacterial diseases classified elsewhere I411 - Myocarditis in viral diseases classified elsewhere I412 - Myocarditis in other infectious and parasitic diseases classified elsewhere I418 - Myocarditis in other diseases classified elsewhere I514 - Myocarditis, unspecified